These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

67 related articles for article (PubMed ID: 29773932)

  • 1. Effectiveness and Tolerability of Therapy With Once-Weekly Exenatide Versus Basal Insulin Among Injectable-Naive Patients With Type 2 Diabetes in a Real-World Setting in the United States.
    Loughlin AM; Qiao Q; Nunes AP; Ezzy SM; Yochum L; Clifford CR; Gately RV; Dore DD; Seeger JD
    Diabetes Spectr; 2018 May; 31(2):129-137. PubMed ID: 29773932
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effectiveness and tolerability of therapy with exenatide once weekly vs basal insulin among injectable-drug-naïve elderly or renal impaired patients with type 2 diabetes in the United States.
    Loughlin AM; Qiao Q; Nunes AP; Öhman P; Ezzy S; Yochum L; Clifford CR; Gately R; Dore DD; Seeger JD
    Diabetes Obes Metab; 2018 Apr; 20(4):898-909. PubMed ID: 29193561
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Tolerability and Effectiveness of Exenatide Once Weekly Relative to Basal Insulin Among Type 2 Diabetes Patients of Different Races in Routine Care.
    Nunes AP; Loughlin AM; Qiao Q; Ezzy SM; Yochum L; Clifford CR; Gately RV; Dore DD; Seeger JD
    Diabetes Ther; 2017 Dec; 8(6):1349-1364. PubMed ID: 28983857
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Glucose Control and Weight Change Associated with Treatment with Exenatide Compared with Basal Insulin: A Retrospective Study.
    Morgan CL; Qiao Q; Grandy S; Johnsson K; Jenkins-Jones S; Holden S; Currie CJ
    Diabetes Ther; 2018 Feb; 9(1):269-283. PubMed ID: 29318537
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Healthcare resource utilization and related financial costs associated with glucose lowering with either exenatide or basal insulin: A retrospective cohort study.
    Holden SE; Morgan CL; Qiao Q; Jenkins-Jones S; Berni ER; Currie CJ
    Diabetes Obes Metab; 2017 Aug; 19(8):1097-1105. PubMed ID: 28218819
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Exenatide once weekly versus daily basal insulin as add-on treatment to metformin with or without a sulfonylurea: a retrospective pooled analysis in patients with poor glycemic control.
    Grimm M; Li Y; Brunell SC; Blase E
    Postgrad Med; 2013 Sep; 125(5):101-8. PubMed ID: 24113668
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparison of extended release GLP-1 receptor agonist therapy versus sitagliptin in the management of type 2 diabetes.
    Stolar MW; Grimm M; Chen S
    Diabetes Metab Syndr Obes; 2013; 6():435-44. PubMed ID: 24285927
    [TBL] [Abstract][Full Text] [Related]  

  • 8. All-cause and diabetes-related healthcare costs among US adults with type 2 diabetes initiating exenatide once weekly or insulin glargine.
    Wittbrodt E; Kong AM; Moore-Schiltz L; Juneau P
    Diabetes Obes Metab; 2018 Mar; 20(3):672-680. PubMed ID: 29083520
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cost-effectiveness analysis of exenatide once-weekly versus dulaglutide, liraglutide, and lixisenatide for the treatment of type 2 diabetes mellitus: an analysis from the UK NHS perspective.
    Chuang LH; Verheggen BG; Charokopou M; Gibson D; Grandy S; Kartman B
    J Med Econ; 2016 Dec; 19(12):1127-1134. PubMed ID: 27310712
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy and safety of exenatide once-weekly vs exenatide twice-daily in Asian patients with type 2 diabetes mellitus.
    Ji L; Onishi Y; Ahn CW; Agarwal P; Chou CW; Haber H; Guerrettaz K; Boardman MK
    J Diabetes Investig; 2013 Jan; 4(1):53-61. PubMed ID: 24843631
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Dynamic risk factors associated with non-severe hypoglycemia in patients treated with insulin glargine or exenatide once weekly.
    Paul SK; Maggs D; Klein K; Best JH
    J Diabetes; 2015 Jan; 7(1):60-7. PubMed ID: 25168883
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Safety and Efficacy of Exenatide Once Weekly in Participants with Type 2 Diabetes and Stage 2/3 Chronic Kidney Disease.
    Guja C; Frías JP; Suchower L; Hardy E; Marr G; Sjöström CD; Jabbour SA
    Diabetes Ther; 2020 Jul; 11(7):1467-1480. PubMed ID: 32306296
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Exenatide once weekly for the treatment of type 2 diabetes mellitus: clinical results in subgroups of patients using different concomitant medications.
    Pencek R; Brunell SC; Li Y; Hoogwerf BJ; Malone J
    Postgrad Med; 2012 Jul; 124(4):33-40. PubMed ID: 22913892
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cost-utility of exenatide once weekly compared with insulin glargine in patients with type 2 diabetes in the UK.
    Beaudet A; Palmer JL; Timlin L; Wilson B; Bruhn D; Boye KS; Lloyd A
    J Med Econ; 2011; 14(3):357-66. PubMed ID: 21563878
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Real-world clinical responses in patients with type 2 diabetes mellitus adding exenatide BID (EBID) or mealtime insulin to basal insulin: a retrospective study using electronic medical record data.
    Lang K; Nguyen H; Huang H; Bauer E; Levin P
    Curr Med Res Opin; 2018 Jun; 34(6):1045-1051. PubMed ID: 29394878
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effect of Once-Weekly Exenatide in Patients With Type 2 Diabetes Mellitus With and Without Heart Failure and Heart Failure-Related Outcomes: Insights From the EXSCEL Trial.
    Fudim M; White J; Pagidipati NJ; Lokhnygina Y; Wainstein J; Murin J; Iqbal N; Öhman P; Lopes RD; Reicher B; Holman RR; Hernandez AF; Mentz RJ
    Circulation; 2019 Nov; 140(20):1613-1622. PubMed ID: 31542942
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Real-world glycemic outcomes in patients with type 2 diabetes initiating exenatide once weekly and liraglutide once daily: a retrospective cohort study.
    Saunders WB; Nguyen H; Kalsekar I
    Diabetes Metab Syndr Obes; 2016; 9():217-23. PubMed ID: 27486339
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The cost-effectiveness of exenatide once weekly compared with exenatide twice daily and insulin glargine for the treatment of patients with type two diabetes and body mass index ≥30 kg/m(2) in Spain.
    Fonseca T; Clegg J; Caputo G; Norrbacka K; Dilla T; Alvarez M
    J Med Econ; 2013 Jul; 16(7):926-38. PubMed ID: 23659201
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparison of trajectories of self-monitored glucose levels by hypoglycemia status over 52 weeks of treatment with insulin glargine or exenatide once weekly.
    Paul SK; Agbeve J; Maggs D; Best JH
    J Diabetes; 2016 Jan; 8(1):148-57. PubMed ID: 25586464
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Once-weekly exenatide as adjunct treatment of type 1 diabetes mellitus in patients receiving continuous subcutaneous insulin infusion therapy.
    Traina AN; Lull ME; Hui AC; Zahorian TM; Lyons-Patterson J
    Can J Diabetes; 2014 Aug; 38(4):269-72. PubMed ID: 24797495
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.